Leerink Partnrs Issues Pessimistic Forecast for TMO Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities researchers at Leerink Partnrs cut their Q1 2026 earnings estimates for Thermo Fisher Scientific in a research note issued to investors on Monday, June 23rd. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $5.89 per share for the quarter, down from their previous estimate of $6.06. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific’s Q2 2026 earnings at $6.05 EPS, Q4 2026 earnings at $7.12 EPS and FY2026 earnings at $25.22 EPS.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The business’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.11 EPS.

Several other equities analysts have also commented on the stock. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Wednesday, May 21st. Wells Fargo & Company lowered their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday, April 24th. Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Royal Bank Of Canada cut their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Finally, UBS Group decreased their target price on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research note on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $604.05.

Thermo Fisher Scientific Stock Up 1.5%

TMO opened at $410.45 on Wednesday. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The stock has a market cap of $154.94 billion, a PE ratio of 24.07, a P/E/G ratio of 2.13 and a beta of 0.78. The business’s fifty day simple moving average is $410.39 and its 200 day simple moving average is $485.33. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $627.88.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. Thermo Fisher Scientific’s payout ratio is 10.09%.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of large investors have recently bought and sold shares of TMO. Cypress Advisory Group LLC bought a new stake in Thermo Fisher Scientific during the fourth quarter worth about $253,000. Intact Investment Management Inc. increased its stake in Thermo Fisher Scientific by 34.0% during the 4th quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company’s stock worth $1,353,000 after acquiring an additional 660 shares during the period. Purkiss Capital Advisors LLC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $1,121,000. LaFleur & Godfrey LLC increased its position in shares of Thermo Fisher Scientific by 9.1% in the fourth quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company’s stock worth $15,486,000 after purchasing an additional 2,488 shares during the period. Finally, Deutsche Bank AG grew its stake in shares of Thermo Fisher Scientific by 9.5% during the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company’s stock worth $687,553,000 after buying an additional 114,277 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.